From professional translators, enterprises, web pages and freely available translation repositories.
a large degree of intersubject variability was noted.
bola zaznamenaná veľká interindividuálna variabilita.
Last Update: 2012-04-12
Usage Frequency: 2
Quality:
intersubject variability in systemic clearance is about 15%.
individuálna 8 variabilita v systémovej klírens je okolo 15%.
Last Update: 2012-04-12
Usage Frequency: 2
Quality:
gender, race and body weight were not predictive in explaining ponatinib pharmacokinetic intersubject variability.
pohlavie, rasa a telesná hmotnosť neboli prediktormi pri vysvetľovaní variability farmakokinetiky ponatinibu medzi pacientmi.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
a low intersubject variability in systemic exposure (coefficient of variation ~25%) was observed.
pri systémovej expozícii sa pozorovala nízka interindividuálna variabilita (koeficient variácie ~25%).
Last Update: 2012-04-12
Usage Frequency: 2
Quality:
however, due to the high intersubject variability some patients may experience large increases in rifabutin exposure and may be at higher risk for rifabutin toxicity.
preto sa pri súčasnom podávaní musí postupovať opatrne.
Last Update: 2011-10-23
Usage Frequency: 1
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
in children between the ages of 2 and 13 years, the clearance of orally administered nelfinavir is approximately 2 to 3 times higher than in adults, with large intersubject variability.
klírens po podaní perorálnej dávky nelfinaviru je u detí vo veku 2 až 13 rokov približne 2- až 3-krát vyšší ako u dospelých s výraznými interindividuálnymi rozdielmi.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
pharmacokinetics in children and the elderly: in children between the ages of 2 and 13 years, the clearance of orally administered nelfinavir is approximately 2 to 3 times higher than in adults, with large intersubject variability.
farmakokinetika u detí a starších pacientov: klírens po podaní perorálnej dávky nelfinaviru je u detí vo veku 2 až 13 rokov približne 2 - až 3- krát vyšší ako u dospelých s výraznými interindividuálnymi rozdielmi.
Last Update: 2012-04-12
Usage Frequency: 4
Quality:
the pharmacokinetics of duloxetine demonstrate large intersubject variability (generally 50-60%), partly due to gender, age, smoking status and cyp2d6 metaboliser status.
farmakokinetika duloxetínu preukazuje veľkú interindividuálnu variabilitu (všeobecne 50–60 %), čiastočne v súvislosti s pohlavím, vekom, fajčiarskymi návykmi a statusom metabolizéra cyp2d6.
Last Update: 2017-04-26
Usage Frequency: 8
Quality:
